3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 2
2
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Unknown
3
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Recurrence
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Interventions
pembrolizumab
109
Cyclophosphamide
85
fludarabine
67
Carboplatin
59
Injections
58
Bevacizumab
52
Specimen Handling
42
Gemcitabine
41
Paclitaxel
40
Magnetic Resonance Spectroscopy
40
venetoclax
38
Nivolumab
38
Cisplatin
37
Dexamethasone
35
Biopsy
34
Temozolomide
31
Docetaxel
29
atezolizumab
27
Oxaliplatin
26
Capecitabine
26
Pemetrexed
25
Fluorouracil
25
toripalimab
24
abemaciclib
24
Irinotecan
24
Azacitidine
24
Fulvestrant
23
Rituximab
21
fludarabine phosphate
20
durvalumab
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Recruiting
×
Infusions, Intravenous
×
Clear all
NCT03850574
2025-08-26
TUSCANY
Aptose Biosciences Inc.
Phase 1/2
Recruiting
240 enrolled